Subscribe Become an Author Sign Up Log In
Private Company


Contact us at to request profile updates/corrections. You must be an official company representative to do so (only requests from corporate emails are accepted).




BenevolentAI uses artificial intelligence to mine and analyse biomedical information, from clinical trails data to academic papers.

Benevolent AI can also use the predictive power of its AI algorithm to design new molecules, extracting new hypothesis based on a knowledge graph composed of over a billion relationships between genes, targets, diseases, proteins and drugs. “When the periodic table of the elements was generated, there were gaps in that table where you know elements had to exist, but they hadn't been discovered,” Hunter says. “We use our knowledge graph like that: what relationship should be present but are not yet known?"

Year Founded
United Kingdom based
$207.0 M
Field/area focus
Chemistry and Biology
Research papers
Business model
  • Own Drug Discovery Programs
Therapeutic focus
  • Neuroscience
  • Rare Diseases
Data type used for modelling
  • EHRs/lab notebooks/databases (structured data mining)
  • Imaging data (MRI scans, diagnostics etc)
  • Network biology analysis (omics)
  • Publications / patents (unstructured data mining)
Drug Discovery Strategy
  • Phenotypic Drug Discovery (PDD)
  • Structure Based Drug Discovery (SBDD)
Product type
  • Small molecules
Research focus
  • Clinical Development
  • Data mining / Ontology building
  • Lead Discovery

Investing history

2018Unknown Round120.0
2015Unknown Round87.0

Industry Partnerships

2016Janssen Pharmaceuticalsdevelop new medicines for hard to treat diseases
2019NovartisThe two companies will investigate indications and responder group(s) for oncology assets currently in clinical development.

Posts Mentioning This Company

Video gallery
Biopharma Insights
Biopharma Insights